

Appl. No. 09/597,796
Amdt. dated January 3, 2006
Response to Notice of Allowance on November 18, 2005

PATENT

Amendments to the Specification:

Please replace the first paragraph on page 1, beginning at line 5, with the following amended paragraph:

-- The present application is a continuation-in-part of U.S. patent application No. 09/287,849, filed April 7, 1999, now U.S. Patent No. 6,627,198, which is a continuation-in-part of U.S. patent application No. 09/223,040, filed December 30, 1998, now U.S. Patent No. 6,580,058, which is continuation-in-part of U.S. patent application No. 09/056,556, filed April 7, 1998, now U.S. Patent No. 6,350,456, ~~which~~ and claims priority to U.S. patent application No. 60/158,338, filed October 7, 1999, and U.S. patent application No. 60/158,425, filed October 7, 1999, and International Application No. PCT/US99/07717, filed April 7, 1999 ~~herein~~ each incorporated herein by reference in its entirety. --

Please replace the 3rd paragraph on Page 4, beginning at line 11, with the following amended paragraph:

-- Figure 2 shows CFUs from spleen cells (Fig. 2A) and lung cells (Fig. 2B) after immunization with MTB72F, MTB59F, MTB 72F DNA, or a composition comprising Ra12, TbH9, and Ra35 antigens. --